Clinical Trial Detail

NCT ID NCT02581943
Title Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Paclitaxel

Pembrolizumab

Carboplatin

Age Groups: adult

No variant requirements are available.